Aiming for safe anticoagulation

New England Journal of Medicine

Volumn 333, Issue 1, 1995, Pages 54-55

  Fihn, Stephan D ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN ISCHEMIA; CLINICAL TRIAL; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; HEART VALVE PROSTHESIS; HEMORRHAGE; HUMAN; PROTHROMBIN TIME; THROMBOEMBOLISM;

EID: 0029041949     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199507063330112     Document Type: Editorial

References (15)

1. Hirsh J, Deykin D, Poller L Therapeutic range for oral anticoagulant therapy. Chest 1986; 89: Suppl: 11S-15S
2. Hirsh J, Dalen JE, Deykin D, Poller L Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992; 102: Suppl: 312S-326S
3. Saour JN, Sieck JO, Mamo LAR, Gallus AS Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-432
4. Altman R, Rouvier J, Gurfinkel E, Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427-431
5. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17
6. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10
7. Kent DL, Vermes D, McDonell M, Henikoff J, Fihn SD A model for planning optimal follow-up for outpatients on warfarin anticoagulation. Med Decis Making 1992; 12: 132-141
8. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153: 1557-1562
9. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991; 229: 351-355
10. Fihn SD, McDonell M, Martin D, Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118: 511-520
11. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241
12. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials Arch Intern Med 1994; 154: 1449-1457 [Erratum, Arch Intern Med 1994;154:2254.]
13. Singer DE. Anticoagulation to prevent stroke in atrial fibrillation. In: DiMarco JP, Prystowski EN, eds. Atrial arrhythmias: state of the art. Armonk, N.Y.: Futura Publishing, 1995:313-26.
14. Fihn SD, McDonell MB, Vermes D, A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. J Gen Intern Med 1994; 9: 131-139
15. White RH, Becker DM, Gunther-Maher MG Outpatient use of a portable international normalized ratio/prothrombin time monitor. South Med J 1994; 87: 206-210